U-shaped association of sleep duration with metabolic syndrome and insulin resistance in patients with type 2 diabetes: The Fukuoka Diabetes Registry

Toshiaki Ohkuma, Hiroki Fujii, Masanori Iwase, Shinako Ogata-Kaizu, Hitoshi Ide, Yohei Kikuchi, Yasuhiro Idewaki, Tamaki Jodai, Yoichiro Hirakawa, Udai Nakamura, Takanari Kitazono

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Objective Sleep duration is suggested to be associated with adverse health outcomes. However, few studies are available on the impact of sleep duration on metabolic syndrome in patients with diabetes, who were at high risk for cardiovascular diseases (CVD). The objective of the present study was to examine the associations of sleep duration with metabolic syndrome and insulin resistance, a major pathophysiologic feature of metabolic syndrome, in patients with type 2 diabetes. Materials/Methods A total of 4402 Japanese patients with type 2 diabetes aged ≥ 20 years were divided into 5 groups according to self-reported sleep duration: Less than 5.5 h, 5.5-6.4 h, 6.5-7.4 h, 7.5-8.4 h, and more than 8.5 h. The associations of sleep duration with metabolic syndrome and other cardiovascular risk factors were examined cross-sectionally. Results The proportions of patients who had metabolic syndrome increased significantly in both patients with shorter and longer sleep duration compared with those with 6.5-7.4 h of sleep (P for quadratic trend < 0.001). This U-shaped association remained significant after adjustment for potential confounders, including total energy intake, current smoking, current drinking and depressive symptoms. Each component of metabolic syndrome also showed similar trends. Furthermore, sleep duration had a quadratic association with homeostasis model assessment of insulin resistance and high sensitivity C-reactive protein. Conclusions Sleep duration was shown to have a U-shaped relationship with metabolic syndrome and insulin resistance, independent of potential confounders, and therefore may be an important modifiable risk factor for CVD prevention in patients with type 2 diabetes.

Original languageEnglish
Pages (from-to)484-491
Number of pages8
JournalMetabolism: Clinical and Experimental
Volume63
Issue number4
DOIs
Publication statusPublished - Apr 2014

Fingerprint

Type 2 Diabetes Mellitus
Registries
Insulin Resistance
Sleep
Cardiovascular Diseases
Metabolic Syndrome X
Energy Intake
C-Reactive Protein
Drinking
Homeostasis
Smoking
Depression
Health

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

U-shaped association of sleep duration with metabolic syndrome and insulin resistance in patients with type 2 diabetes : The Fukuoka Diabetes Registry. / Ohkuma, Toshiaki; Fujii, Hiroki; Iwase, Masanori; Ogata-Kaizu, Shinako; Ide, Hitoshi; Kikuchi, Yohei; Idewaki, Yasuhiro; Jodai, Tamaki; Hirakawa, Yoichiro; Nakamura, Udai; Kitazono, Takanari.

In: Metabolism: Clinical and Experimental, Vol. 63, No. 4, 04.2014, p. 484-491.

Research output: Contribution to journalArticle

Ohkuma, Toshiaki ; Fujii, Hiroki ; Iwase, Masanori ; Ogata-Kaizu, Shinako ; Ide, Hitoshi ; Kikuchi, Yohei ; Idewaki, Yasuhiro ; Jodai, Tamaki ; Hirakawa, Yoichiro ; Nakamura, Udai ; Kitazono, Takanari. / U-shaped association of sleep duration with metabolic syndrome and insulin resistance in patients with type 2 diabetes : The Fukuoka Diabetes Registry. In: Metabolism: Clinical and Experimental. 2014 ; Vol. 63, No. 4. pp. 484-491.
@article{22d6dcfd8ebc419885c47ed68c4aeedc,
title = "U-shaped association of sleep duration with metabolic syndrome and insulin resistance in patients with type 2 diabetes: The Fukuoka Diabetes Registry",
abstract = "Objective Sleep duration is suggested to be associated with adverse health outcomes. However, few studies are available on the impact of sleep duration on metabolic syndrome in patients with diabetes, who were at high risk for cardiovascular diseases (CVD). The objective of the present study was to examine the associations of sleep duration with metabolic syndrome and insulin resistance, a major pathophysiologic feature of metabolic syndrome, in patients with type 2 diabetes. Materials/Methods A total of 4402 Japanese patients with type 2 diabetes aged ≥ 20 years were divided into 5 groups according to self-reported sleep duration: Less than 5.5 h, 5.5-6.4 h, 6.5-7.4 h, 7.5-8.4 h, and more than 8.5 h. The associations of sleep duration with metabolic syndrome and other cardiovascular risk factors were examined cross-sectionally. Results The proportions of patients who had metabolic syndrome increased significantly in both patients with shorter and longer sleep duration compared with those with 6.5-7.4 h of sleep (P for quadratic trend < 0.001). This U-shaped association remained significant after adjustment for potential confounders, including total energy intake, current smoking, current drinking and depressive symptoms. Each component of metabolic syndrome also showed similar trends. Furthermore, sleep duration had a quadratic association with homeostasis model assessment of insulin resistance and high sensitivity C-reactive protein. Conclusions Sleep duration was shown to have a U-shaped relationship with metabolic syndrome and insulin resistance, independent of potential confounders, and therefore may be an important modifiable risk factor for CVD prevention in patients with type 2 diabetes.",
author = "Toshiaki Ohkuma and Hiroki Fujii and Masanori Iwase and Shinako Ogata-Kaizu and Hitoshi Ide and Yohei Kikuchi and Yasuhiro Idewaki and Tamaki Jodai and Yoichiro Hirakawa and Udai Nakamura and Takanari Kitazono",
year = "2014",
month = "4",
doi = "10.1016/j.metabol.2013.12.001",
language = "English",
volume = "63",
pages = "484--491",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - U-shaped association of sleep duration with metabolic syndrome and insulin resistance in patients with type 2 diabetes

T2 - The Fukuoka Diabetes Registry

AU - Ohkuma, Toshiaki

AU - Fujii, Hiroki

AU - Iwase, Masanori

AU - Ogata-Kaizu, Shinako

AU - Ide, Hitoshi

AU - Kikuchi, Yohei

AU - Idewaki, Yasuhiro

AU - Jodai, Tamaki

AU - Hirakawa, Yoichiro

AU - Nakamura, Udai

AU - Kitazono, Takanari

PY - 2014/4

Y1 - 2014/4

N2 - Objective Sleep duration is suggested to be associated with adverse health outcomes. However, few studies are available on the impact of sleep duration on metabolic syndrome in patients with diabetes, who were at high risk for cardiovascular diseases (CVD). The objective of the present study was to examine the associations of sleep duration with metabolic syndrome and insulin resistance, a major pathophysiologic feature of metabolic syndrome, in patients with type 2 diabetes. Materials/Methods A total of 4402 Japanese patients with type 2 diabetes aged ≥ 20 years were divided into 5 groups according to self-reported sleep duration: Less than 5.5 h, 5.5-6.4 h, 6.5-7.4 h, 7.5-8.4 h, and more than 8.5 h. The associations of sleep duration with metabolic syndrome and other cardiovascular risk factors were examined cross-sectionally. Results The proportions of patients who had metabolic syndrome increased significantly in both patients with shorter and longer sleep duration compared with those with 6.5-7.4 h of sleep (P for quadratic trend < 0.001). This U-shaped association remained significant after adjustment for potential confounders, including total energy intake, current smoking, current drinking and depressive symptoms. Each component of metabolic syndrome also showed similar trends. Furthermore, sleep duration had a quadratic association with homeostasis model assessment of insulin resistance and high sensitivity C-reactive protein. Conclusions Sleep duration was shown to have a U-shaped relationship with metabolic syndrome and insulin resistance, independent of potential confounders, and therefore may be an important modifiable risk factor for CVD prevention in patients with type 2 diabetes.

AB - Objective Sleep duration is suggested to be associated with adverse health outcomes. However, few studies are available on the impact of sleep duration on metabolic syndrome in patients with diabetes, who were at high risk for cardiovascular diseases (CVD). The objective of the present study was to examine the associations of sleep duration with metabolic syndrome and insulin resistance, a major pathophysiologic feature of metabolic syndrome, in patients with type 2 diabetes. Materials/Methods A total of 4402 Japanese patients with type 2 diabetes aged ≥ 20 years were divided into 5 groups according to self-reported sleep duration: Less than 5.5 h, 5.5-6.4 h, 6.5-7.4 h, 7.5-8.4 h, and more than 8.5 h. The associations of sleep duration with metabolic syndrome and other cardiovascular risk factors were examined cross-sectionally. Results The proportions of patients who had metabolic syndrome increased significantly in both patients with shorter and longer sleep duration compared with those with 6.5-7.4 h of sleep (P for quadratic trend < 0.001). This U-shaped association remained significant after adjustment for potential confounders, including total energy intake, current smoking, current drinking and depressive symptoms. Each component of metabolic syndrome also showed similar trends. Furthermore, sleep duration had a quadratic association with homeostasis model assessment of insulin resistance and high sensitivity C-reactive protein. Conclusions Sleep duration was shown to have a U-shaped relationship with metabolic syndrome and insulin resistance, independent of potential confounders, and therefore may be an important modifiable risk factor for CVD prevention in patients with type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=84896487906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896487906&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2013.12.001

DO - 10.1016/j.metabol.2013.12.001

M3 - Article

C2 - 24411997

AN - SCOPUS:84896487906

VL - 63

SP - 484

EP - 491

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 4

ER -